Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. (NYSE: AVTR) is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. This news page aggregates company announcements, earnings updates and other disclosures so readers can follow how Avantor’s operations, portfolio and governance evolve over time.
Recent news releases describe Avantor’s participation in investor conferences, quarterly earnings reports, leadership and board appointments, and product and service developments. Examples include announcements about the timing of quarterly and full-year earnings releases and related conference calls, as well as participation in events such as the J.P. Morgan Healthcare Conference. These items provide context on how the company communicates with the investment community and presents its financial performance.
Product- and operations-focused news highlights areas such as bioprocessing, biomanufacturing and laboratory services. Avantor has reported the launch of a sterile sampling platform and PUPSIT assemblies for bioprocessing, the development of a biodegradable viral inactivation detergent recognized with an Edison Patent Award, and the expansion of its Centralized Service Center model with a facility serving the Greater Boston area. These updates illustrate how the company positions its tools and services within scientific and industrial workflows.
Corporate governance news includes the appointment of new directors and senior executives, such as additions to the Board of Directors and the creation of an Executive Vice President and Chief Operating Officer role. Together, these news items offer insight into Avantor’s strategic priorities, leadership changes and ongoing initiatives. Investors, analysts and industry participants can use this page to monitor company communications and official announcements over time.
Avantor (AVTR) reported Q4 2024 results with net sales of $1.69 billion, showing a 2% decrease but 1% organic growth. Q4 net income reached $500.4 million with adjusted EBITDA of $307.7 million. Diluted GAAP EPS was $0.73 and adjusted EPS $0.27.
For full year 2024, net sales were $6.78 billion, declining 3% with a 2% organic decrease. Annual net income was $711.5 million with adjusted EBITDA of $1,198.8 million. The company achieved operating cash flow of $840.8 million and free cash flow of $768.3 million.
By segment, Laboratory Solutions reported Q4 sales of $1.13 billion, down 5%, while Bioscience Production showed Q4 sales of $560.8 million, up 4%. The company's bioprocessing platform grew high-single-digits, with management expressing confidence in achieving near-term and long-term financial goals.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has announced a strategic partnership with Avantor, Inc. (NYSE: AVTR) to expand its nucleic acid products distribution across Europe, Middle East, and Africa (EMEA). The collaboration aims to streamline ordering processes and reduce lead times for European customers.
The partnership will increase accessibility to TriLink's product portfolio, including CleanCap® cap analogs, catalog mRNAs, modified and unmodified nucleotides, and CleanScribe® RNA Polymerase. These products will be available for research use only (RUO) or at GMP-grade through VWR's eCommerce platform, MarketSource.
TriLink, with over 25 years of experience in nucleic acid development, offers CDMO services and specializes in mRNA capping analogs, including CleanCap® M6, mRNA raw materials, and advanced scale-up capabilities.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced it will release its fourth quarter and full year 2024 financial results before market opens on Friday, February 7, 2025.
The company will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. A live audio webcast will be available in the Events & Presentations section of Avantor's investor website, with a replay accessible for 30 days.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services for life sciences and advanced technology industries, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Michael Stubblefield, President and CEO, will deliver a presentation at The Westin St. Francis Hotel in San Francisco on January 15, 2025, at 8:15 a.m. Pacific Standard Time.
Interested parties can access a live audio webcast of the session through the Events & Presentations section in the Investor area of Avantor's website at ir.avantorsciences.com. The webcast recording will remain available for replay for 30 days following the presentation.
Avantor (NYSE: AVTR), a global provider of mission-critical products and services for life sciences and advanced technology industries, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. President and CEO Michael Stubblefield will join a fireside chat on December 3 at 9:10 a.m. EST in Coral Gables, Florida.
The session will be available via live audio webcast through the Events & Presentations section of Avantor's investor website, with a replay accessible for 30 days following the event.
Quantum-Si (Nasdaq: QSI) has entered into a distribution agreement with Avantor (NYSE: AVTR) for its Next-Generation Protein Sequencing (NGPS) technology portfolio in the U.S. and Canadian markets. The collaboration will enable broader access to QSI's proteomics solutions across various laboratory settings. The platform utilizes single-molecule sequencing technology for protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis, supporting applications in drug discovery, diagnostics, and clinical research.
Avantor (NYSE: AVTR) announced the opening of its new flagship Bridgewater Innovation Center in New Jersey. The 60,000-square-foot facility doubles the previous laboratory and pilot plant capacity, featuring dedicated spaces for upstream and downstream process development, analytical testing labs, and a viral vector laboratory. The center, part of Avantor's global network of 13 research facilities, is staffed with Ph.D. scientists, bioengineers, and process engineers to support biomanufacturing optimization and accelerate development of therapies including monoclonal antibodies, cell and gene therapy, and mRNA workflows.
Avantor (NYSE: AVTR) has appointed Dame Louise Makin to its Board of Directors, effective until the 2025 Annual Meeting of Stockholders. Dame Louise, former CEO of BTG plc for 15 years, brings significant healthcare industry experience, having led BTG's transformation through organic growth and acquisitions until its acquisition by Boston Scientific in 2019. She previously held leadership positions at Baxter Healthcare, including President of Biopharmaceuticals Europe. Currently, she serves as non-executive chair of Halma plc and has served on multiple corporate boards. Dame Louise holds a Ph.D. in material sciences from Cambridge and an MBA from The Open University.
Avantor (NYSE: AVTR) reported Q3 2024 financial results with net sales of $1.71 billion, showing a slight decrease of 0.3% (0.7% organic decline). Net income decreased to $57.8 million from $108.4 million in Q3 2023, with diluted EPS of $0.08 and adjusted EPS of $0.26. The company achieved strong free cash flow of $204.0 million, leading to increased full-year guidance. Laboratory Solutions segment saw 1.1% growth, while Bioscience Production decreased by 3.2%. The company maintains its outlook for mid to high single-digit growth in bioprocessing, with cost transformation programs running ahead of plan.
Avantor (NYSE: AVTR) has expanded its partnership with the National Institute for Bioprocessing Research and Training (NIBRT) to address biopharma manufacturing challenges. The collaboration focuses on downstream optimization for monoclonal antibodies (mAbs) through advanced equipment provision and specialized training. Avantor will supply Masterflex® pump systems and single-use systems to create realistic biopharmaceutical workflows in NIBRT's training facilities. The partnership aims to tackle scale-up challenges, optimize fluid handling processes, and enhance manufacturing efficiency through expert-led training sessions.